Company intelligence / Profile preview

SK bioscience

Seongnam-si, South Koreaskbioscience.com ↗

Ownership: Public · 302440
Employees: ~1101
Development stage: Commercial

Overview

Successfully developed South Korea's first COVID-19 vaccine (SKYCovione™). Phase III trials completed for next-gen pneumococcal vaccine with Sanofi. WHO-prequalified vaccines including SKYCellflu® and SKYVaricella®.

Therapeutic areas: Psychiatry
Modalities: Recombinant proteins
Industry: Biotech

Drug pipeline

23 assets

Skyvaricella

22 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on SK bioscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SK bioscience.

Explore the full profile